P-008 Plasma lipidome of patients with advanced colorectal cancer
نویسندگان
چکیده
منابع مشابه
Lipidome in colorectal cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths. Understanding its pathophysiology is essential for developing efficient strategies to treat this disease. Lipidome, the sum of total lipids, related enzymes, receptors and signaling pathways, plays crucial roles in multiple cellular processes, such as metabolism, energy storage, proliferation and apoptosis. Dysregulat...
متن کاملPlasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer.
OBJECTIVE Plasma D-dimer levels are elevated in patients with a variety of solid tumors. Recently, it has been reported that the level before curative surgery is a prognostic factor for colorectal cancer (CRC). We investigated whether the plasma D-dimer level before systemic chemotherapies is a predictor for advanced or recurrent unresectable CRC. METHODS This study included 42 patients treat...
متن کاملOverexpression of cancer stem cell marker Lgr5 in colorectal cancer patients and association with pathologic findings
Background: To determine the expression of cancer stem cell marker Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) in colorectal carcinoma samples compared to normal adjacent tissue and any possible association with clinicopathological findings. Methods: This study was performed on forty samples of cancerous colorectal tissues (case group) and their adjacent normal mucosa (c...
متن کاملChemotherapy in Advanced Colorectal Cancer Patients
Colorectal cancer is one of the most common cancers worldwide (Huang et al., 2004). In China, with lifestyle being continuously westernized, the incidence of colorectal cancer has been on the rise, and also one of the most common cancers without sex difference. Although 40% to 50% colorectal cancer patients can be treated by surgery, many will die due to recurrence or metastasis. As for unresec...
متن کامل89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
Monoclonal antibodies (mAbs) against the epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer (mCRC). Approximately 50% of patients benefit despite patient selection for RAS wild type (wt) tumors. Based on the hypothesis that tumor targeting is required for clinical benefit of anti-EGFR treatment, biodistribution and tumor uptake of (89)Zr-cetuximab by...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2016
ISSN: 0923-7534
DOI: 10.1093/annonc/mdw199.08